| |
 | |  |
|
| |
|
New Paper in Science Features Infinity's IPI-926 Hedgehog Pathway Inhibitor as a Promising New Approach in Chemo-Resistant Pancreatic Cancer
(29/May/2009)
|
|
CAMBRIDGE, Mass., May 29, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new scientific paper further supporting Hedgehog signaling pathway inhibition as a promising new approach to treat cancer. The data featured in the paper show that IPI-926, when administered in combination with gemcitabine in a preclinical mouse model of treatment-resistant pancreatic cancer, increased tumor cell death, resulting in a reduction of
|
|
|
Cornerstone Pharmaceuticals Initiates Phase I/II Combination Therapy Clinical Trial Of CPI-613 For Treatment Of Pancreatic Cancer
(28/May/2009)
|
|
Cornerstone Pharmaceuticals, Inc., a privately-held pharmaceutical company, announced today that it has begun a phase I/II clinical trial of CPI-613, the initial candidate to emerge from the company's Altered Energy Metabolism Directed technology platform. (Source: Pharmaceutical Online News)
|
|
|
Pancreatic Cancer Research Receives $18 Million Boost
(28/May/2009)
|
|
The Translational Genomics Research Institute (TGen) and the University of Pennsylvania (Penn) will receive $18 million to research pancreatic cancer, Stand Up to Cancer (SU2C) has announced. Dr. Daniel Von Hoff, TGen's Physician-In-Chief, and Dr. Craig B. (Source: Health News from Medical News Today)
|
|
|
How Viral Infection Can Protect From Type 1 Diabetes
(28/May/2009)
|
|
Type 1 diabetes is caused by immune system–mediated destruction of insulin-producing beta-cells in the pancreas. It is known that infection with a virus can induce an immune response that damages beta-cells or a response that protects an individual from type 1 diabetes. (Source: ScienceDaily Headlines)
|
|
|
$18 million awarded to TGen and University of Pennsylvania for pancreatic cancer research
(27/May/2009)
|
|
(The Translational Genomics Research Institute) Dr. Daniel Von Hoff, TGen's Physician-In-Chief, and Dr. Craig B. Thompson, Director of the Abramson Cancer Center at Penn, are co-leaders of SU2C pancreatic cancer "Dream Team.'' (Source: EurekAlert! - Medicine and Health)
|
|
|
Queensland Government Funds Univeristy Of Queensland Cancer Fight
(25/May/2009)
|
|
University of Queensland (UQ) researchers will use a $5 million grant from the Queensland State Government to unlock the genetic causes of pancreatic and ovarian cancer. The funding was announced overnight by Queensland Trade Minister Stephen Robertson at the world's largest biotechnology conference, Bio, in Atlanta, USA. (Source: Health News from Medical News Today)
|
|
|
Low blood supply limits cancer drug
(23/May/2009)
|
|
Scientists have discovered a new mechanism that may explain why pancreatic cancer patients are often resistant to a common chemotherapy treatment (Source: Pharmacy Europe)
|
|
|
Wash. Has 1st Death Under New Suicide Law
(22/May/2009)
|
|
A 66-year-old woman who had stage 4 pancreatic cancer is the first person to die under Washington state's new assisted suicide law. (Source: Health News: CBSNews.com)
|
|
|
Study Shows Pancreatic Cancer Drug May Fail
(22/May/2009)
|
|
A poor network of blood vessels may explain why some people with pancreatic cancer are often resistant to a common chemotherapy treatment, international researchers said on Thursday. (Source: Health Behavior News Digest)
|
|
|
Wash. Woman Dies Under New Assisted Suicide Law
(22/May/2009)
|
|
A 66-year-old woman who had pancreatic cancer has become the first person to die under Washington state's new assisted suicide law. (Source: FOXNews.com)
|
|
|
Pancreas cancer drug failure clue
(22/May/2009)
|
|
Experts believe they have discovered why pancreatic cancer can be so resistant to drug treatment. (Source: BBC News | Health | UK Edition)
|
|
|
AlphaVax Announces Full Enrollment In Phase I/II Study Of Active Immunotherapy In Patients With Advanced Or Metastatic Cancer
(20/May/2009)
|
|
RESEARCH TRIANGLE PARK, N.C. -- AlphaVax announced today the completion of enrollment in a Phase I/II CEA cancer immunotherapy study being conducted by the Duke University Comprehensive Cancer Center, Durham, NC. This Phase I/II study is an open-label, dose-escalation study to evaluate the safety and immunogenicity of carcinoembryonic antigen (CEA(6D))-expressing virus-like replicon particle (VRP) immunotherapy in patients with advanced or metastatic CEA-expressing malignancies. CEA is tumor protein found on many types of cancer including colorectal, pancreatic,
|
|
|
Multivitamins May Help Women Live Longer: Study
(20/May/2009)
|
|
LOS ANGELES -- Multivitamins might prolong life for women by preventing parts of their DNA from shortening, a new study has found. Researchers at the U.S. National Institute of Environmental Health Sciences (NIEHS) analyzed data on 586 women participating in the Sisters Study, which included women who had breast cancer and their cancer-free siblings, according to the HealthDay News on Monday. As part of that study, the women were asked about their use of vitamin supplements
|
|
|
Heavy Drinking Can Raise Risk of Pancreatic Cancer
(20/May/2009)
|
|
Long-term heavy drinkers were 1.6 times more likely to develop pancreatic cancer than nondrinkers, according to researchers at Maastricht University in the Netherlands. (Source: Alcohol, Tobacco and Other Drugs News)
|
|
|
Type Of Connection Procedure After Pancreatic Surgery Influenced Rate Of Pancreatic Fistula
(19/May/2009)
|
|
After surgery to remove the head of the pancreas, invagination of the pancreas into the small intestine resulted in a lower rate of pancreatic fistula, according to researchers at the Jefferson Pancreas, Biliary and Related Cancer Center. The research was published in the Journal of the American College of Surgeons. It was performed as a randomized trial the gold standard for studies. Removing the head of the pancreas, a procedure called pancreaticoduodenectomy (PD), is a common
|
|
|
Dialing Up The Degrees To Fight Cancer
(16/May/2009)
|
|
"My wish is simple, but I wouldn't have given it a second thought this time last year," Joe Castelli said as his eyes welled up with tears. "I want to see my children grow up. I have two daughters who are nine and seven." This longing began soon after he felt pain on his left side last summer. After taking Ibuprofen for a couple of weeks, his physician did a CAT scan. (Source: Health News
|
|
|
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development Of OnaltaTM
(15/May/2009)
|
|
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). (Source: Health News from Medical News Today)
|
|
|
GenWay Biotech obtains exclusive rights to AMDL's DR-70 cancer test in US and Canada
(15/May/2009)
|
|
(GenWay Biotech) International studies have linked the DR-70 cancer test to at least 14 different types of cancer, including lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, brain and pancreatic cancer making it one of the most versatile cancer biomarkers available. (Source: EurekAlert! - Cancer)
|
|
|
MiR-196a Promotes The Metastases Of Tumors
(14/May/2009)
|
|
MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins. High levels of miR-196a, a microRNA suppressing the expression of specific homebox genes that are of high relevance for the development of the human embryo, activated oncogenic pathways inside human tumor cells and induced tumor cell dissemination. (Source: Health News from Medical News Today)
|
|
|
Researchers Focus On Targeted Radiation For Pancreatic Cancer Tumors
(14/May/2009)
|
|
According to the American Cancer Society, pancreatic cancer is the fourth leading cancer killer in the country, with more than 42,000 new cases expected to be diagnosed this year and more than 35,000 deaths. In New Jersey alone, 1,000 deaths are estimated from the disease, which only has a five-year, five-percent survival rate. (Source: Health News from Medical News Today)
|
|
| |
| | |
|
